Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage whose objective is to develop and provide patients with new therapies. The focus of the company’s research and developmentdepartment targets three promising areas, namely fibrotic diseases, the treatment of certain forms of lysosomal diseases and oncology with a priority for the development of indications for orphan diseases for which the unmet medical need and the regulations in force allow an accelerated development.
Inventiva has developed a recognized expertise in the field of nuclear receptors, transcription factors and epigenetic modulation, which are sources of innovative therapeutic targets. This expertise combined with the research platform, including biology teams, screening equipment, chemistry, ADME and pharmacology resources, as well as its own library of 240,000 compounds, enables the company to develop a regular flow of drug candidates. The product pipeline is rich and diversified with two products (IVA337 and IVA336) at clinical stage, two research partnerships, one of which a clinical stage, with AbbVie and Boehringer Ingelheim, as well as several innovative projects at preclinical stage.
Inventiva is a public company traded on Euronext Paris.